Literature DB >> 11172089

The role of MKK1/2 kinase activity in human cytomegalovirus infection.

Robert A Johnson1, Xiu-Li Ma1, Andrew D Yurochko1, Eng-Shang Huang1.   

Abstract

Human cytomegalovirus infection of quiescent fibroblasts was found to induce a bi-phasic activation of mitogen-activated protein kinase (MAPK) kinase 1 and 2 (MKK1/2) and two of their downstream targets, extracellular signal regulated kinase 1 and 2 (ERK1/2), as determined by Western blot analysis using phospho-specific antibodies. Treatment of infected fibroblasts with U0126, a potent and specific inhibitor of MKK1/2 kinase activity, completely blocked ERK1/2 activation following HCMV infection without affecting cell viability. Anti-viral studies demonstrate that in the presence of U0126, viral titres are reduced and viral DNA replication is inhibited. In addition, protein levels of two viral early genes that are required for viral DNA replication, UL44 and UL84, are significantly decreased in the presence of U0126. These results suggest that HCMV-mediated activation of MKK1/2 kinase activity enhances virus infectivity by ensuring timely initiation of viral DNA replication, possibly by regulating early gene expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172089     DOI: 10.1099/0022-1317-82-3-493

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  48 in total

1.  Role of regulatory elements and the MAPK/ERK or p38 MAPK pathways for activation of human cytomegalovirus gene expression.

Authors:  Jiping Chen; Mark F Stinski
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Combined agonist-antagonist genome-wide functional screening identifies broadly active antiviral microRNAs.

Authors:  Diwakar Santhakumar; Thorsten Forster; Nouf N Laqtom; Rennos Fragkoudis; Paul Dickinson; Cei Abreu-Goodger; Sergei A Manakov; Nila Roy Choudhury; Samantha J Griffiths; Annaleen Vermeulen; Anton J Enright; Bernadette Dutia; Alain Kohl; Peter Ghazal; Amy H Buck
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

3.  Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection.

Authors:  Laura J Terry; Livia Vastag; Joshua D Rabinowitz; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

4.  Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway.

Authors:  Honglin Luo; Bobby Yanagawa; Jingchun Zhang; Zongshu Luo; Mary Zhang; Mitra Esfandiarei; Christopher Carthy; Janet E Wilson; Decheng Yang; Bruce M McManus
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Herpes simplex virus ICP27 activation of stress kinases JNK and p38.

Authors:  Danna Hargett; Tim McLean; Steven L Bachenheimer
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Synaptic vesicle-like lipidome of human cytomegalovirus virions reveals a role for SNARE machinery in virion egress.

Authors:  Sean T H Liu; Ronit Sharon-Friling; Pavlina Ivanova; Stephen B Milne; David S Myers; Joshua D Rabinowitz; H Alex Brown; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

7.  Suppression of coronavirus replication by inhibition of the MEK signaling pathway.

Authors:  Yingyun Cai; Yin Liu; Xuming Zhang
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells.

Authors:  Thorsten Eierhoff; Eike R Hrincius; Ursula Rescher; Stephan Ludwig; Christina Ehrhardt
Journal:  PLoS Pathog       Date:  2010-09-09       Impact factor: 6.823

Review 9.  Chronic viral infection and primary central nervous system malignancy.

Authors:  Robert Saddawi-Konefka; John R Crawford
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-13       Impact factor: 4.147

Review 10.  Potential of protein kinase inhibitors for treating herpesvirus-associated disease.

Authors:  Renfeng Li; S Diane Hayward
Journal:  Trends Microbiol       Date:  2013-04-19       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.